Actively Recruiting

Early Phase 1
Age: 21Years - 45Years
All Genders
Healthy Volunteers
ID05846451

Evaluating How Kratom Affects Oxycodone Processing and Effects Study of Potential Kratom-Oxycodone Interaction with Clinical Measures

Led by Washington State University · Updated on 2024-12-20

16

Participants Needed

1

Research Sites

100 weeks

Total Duration

On this page

Sponsors

W

Washington State University

Lead Sponsor

N

National Center for Complementary and Integrative Health (NCCIH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating how the botanical product kratom influences the way the body processes the opioid drug oxycodone and whether kratom changes oxycodone's effects on the body. This early phase 1 study focuses on both the pharmacokinetic interaction, meaning how oxycodone is broken down and removed from the body, and the pharmacodynamic interaction, by measuring pupil diameter as a sensitive indicator of opioid effects on the central nervous system. Healthy adults aged 21 to 45 are participating to provide insight into these interactions. Participants will complete four study arms involving different combinations of kratom and oxycodone administration. These include a single dose of kratom tea, a single oral dose of immediate-release oxycodone tablet, both kratom tea and oxycodone given together, and kratom tea taken daily at home for four days followed by kratom tea and oxycodone given together in the research setting. The kratom tea is made by stirring 2 grams of dry leaf powder in hot water and cooled before drinking. During the study, participants will undergo assessments including measuring oxycodone levels in the blood over 24 hours to examine drug metabolism with and without kratom. Researchers will measure pupil size to evaluate opioid effects and monitor safety throughout. Participants must comply with dietary and medication restrictions and attend visits, with total involvement lasting as long as the four study arms require. This design aims to clarify how kratom may affect oxycodone's behavior and impact in the body.

CONDITIONS

Official Title

Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints

Who Can Participate

Age: 21Years - 45Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthy males and females aged 21 to 45 years
  • Body weight between 130 and 250 pounds (60-115 kg) and body mass index between 19 and 30
  • Not currently taking medications or supplements known to affect oxycodone or kratom metabolism
  • Willing to avoid supplements, botanical products, and fruit juices for several weeks
  • Willing to abstain from cannabis, hemp, THC, and CBD products for several weeks
  • Willing to avoid caffeinated beverages the evening before and morning of inpatient visits
  • Willing to avoid alcohol for one day before inpatient visits
  • Willing to use non-hormonal contraception methods
  • Have previously consumed kratom and tolerated it well
  • Willing to abstain from kratom for several weeks
  • Have previously used any opioid and tolerated it well without unpleasant effects or addiction
  • Able to give written informed consent and comply with study requirements
  • Reside within 40 miles of Spokane and have time to participate
Not Eligible

You will not qualify if you...

  • Under 21 or over 45 years of age
  • Weigh less than 130 pounds or more than 250 pounds
  • Body mass index less than 19 or greater than 30
  • Current major or chronic illnesses such as kidney, liver, diabetes, heart, lung diseases, cancer, or HIV/AIDS
  • No prior exposure to kratom
  • No prior exposure to opioids
  • History of anemia or significant blood disorders
  • History of substance abuse, dependence, addiction, or major psychiatric illness
  • Need for chronic opioid pain medications
  • Use of opioid pain medications within 3 weeks before study start
  • Expected need for opioid pain medications soon (e.g., planned surgery)
  • Pregnant or nursing
  • Allergy or intolerance to kratom, opioids, or oxycodone
  • Taking medications or supplements that affect kratom or oxycodone metabolism
  • Any condition that may compromise participant safety or data quality
  • History of sleep apnea
  • Previous recreational use of drugs like amphetamines, benzodiazepines, cocaine, MDMA, PCP, or opioids
  • Use of cannabis, hemp, THC, or CBD products within the last month
  • Laboratory values outside normal range posing health risks
  • Inability to speak, read, and understand English

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Washington State University College of Pharmacy and Pharmaceutical Sciences

Spokane, Washington, United States, 99202

Actively Recruiting

Loading map...

Research Team

M

Mary Paine, PhD

D

Deena Hadi, BS

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

4

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here